Long Position on PCVX @ $45.00 on 11/10/2022 (Momentum)

Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology vaccine company. 

The Company develops novel protein vaccines to prevent or treat bacterial infectious diseases.

Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.

The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. 

Shares have formed a bullish "flag" after the company reported positive results and used the opporutinity to sell shares. The Company said VAX-24's phase 1/2 trial of healthy adults 18-64 met its primary safety and tolerability targets and was similar in that way to Pfizer's Prevnar 20 and could be a best-in-class pneumonia vaccine.

The Company is advancing VAX-24 in Adult and Pediatric Populations with Submission of Infant Investigational New Drug (IND) Application and Study Initiation Expected in First Half of 2023. The full six-month safety follow-up is ongoing for the Phase 2 portion of the study. 

Higher share prices are expected.

Entry Point: $45.00

Stop Loss: $42.00

Trading Range: $16.78 to $46.02

Target Price: $50.00

Position closed on 12/14/2022 at price of $46.00 with a 2.22% gain in 33 days.

Back to Portfolio